Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization

Hernández-Parra, Héctor; Cortés, Hernán; Ávalos-Fuentes, José Arturo; Prado-Audelo, María Del; Florán, Benjamí­n; Leyva‐Gómez, Gerardo; Sharifi‐Rad, Javad; Cho, William C.

doi:10.1186/s12951-022-01612-5

Cited by 12 publications

(10 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug repositioning, or repurposing, is a strategy to identify new therapeutic uses for existing drugs [ 95 , 96 , 97 ], a promising approach with several limitations. Repositioned drugs are not so immediately applicable to therapy.…”

Section: Discussionmentioning

confidence: 99%

Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat

Hay Mele,

Rossetti,

Cubellis

et al. 2024

Genes

View full text Add to dashboard Cite

Rare diseases, or orphan diseases, are defined as diseases affecting a small number of people compared to the general population. Among these, we find lysosomal storage disorders (LSDs), a cluster of rare metabolic diseases characterized by enzyme mutations causing abnormal glycolipid storage. Drug repositioning involves repurposing existing approved drugs for new therapeutic applications, offering advantages in cost, time savings, and a lower risk of failure. We present a comprehensive analysis of existing drugs, their repurposing potential, and their clinical implications in the context of LSDs, highlighting the necessity of mutation-specific approaches. Our review systematically explores the landscape of drug repositioning as a means to enhance LSDs therapies. The findings advocate for the strategic repositioning of drugs, accentuating its role in expediting the discovery of effective treatments. We conclude that drug repurposing represents a viable pathway for accelerating therapeutic discovery for LSDs, emphasizing the need for the careful evaluation of drug efficacy and toxicity in disease-specific contexts.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat

Hay Mele,

Rossetti,

Cubellis

et al. 2024

Genes

View full text Add to dashboard Cite

show abstract

“…It is predicted as 13 million people will be affected by Parkinson's disease in 2040. 1 Aging and Parkinson's disease have a high correlation, and we need to pay close attention to the treatment and management of Parkinson's disease. Despite the seriousness of Parkinson's disease, the current treatments only provide symptomatic relief and do not stop the progression of the disease.…”

Section: Introductionmentioning

confidence: 99%

Drug repurposing for Parkinson’s disease by biological pathway based edge-weighted network proximity analysis

Han,

Jung,

Lee

2024

Preprint

View full text Add to dashboard Cite

Parkinson’s disease is the second most frequent neurodegenerative disease, and its severity is increasing with extended life expectancy. Most of current treatments tend to rely on symptomatic relief and there are multiple trials for treatments that target the causes of the disease. The mechanisms underlying neurodegenerative diseases are intricate, and understanding the interplay among the biological elements involved is crucial. These relationships can be effectively analyzed through biological networks, and the application of network-based analyses in the context of neurodegenerative disease treatment has gained significant attention. Moreover, considering the significance differences in interactions between biological elements within the network is important. In this context, we introduce a novel biological pathway based edge-weighted network construction method for drug repurposing in Parkinson’s disease. The interaction found in multiple Parkinson’s disease-related pathways have more significance than other interactions, and this significance is reflected in the network edge weights. Using the edge-weighted network construction method, we found a significant difference in the efficacy between known and unknown Parkinson’s disease drugs. The method predicts drug-disease interactions more accurately than approaches that do not consider the significance differences among interactions, and the paths between the drug and disease within the network correspond to the drug’s mechanism of action. In summary, we propose a network-based drug repurposing method using the biological pathway based edge-weighted network.

show abstract

“…Parkinson’s disease (PD) is a common chronic progressive neurodegenerative disease, ranking as the second most common neurodegenerative disease only after Alzheimer’s disease. − The exact cause of PD is still unclear, and most scholars currently believe that PD is pathologically related to the degeneration of dopamine neurons in the substantia nigra . Nowadays, the diagnosis of PD currently relies on medical history and clinical symptoms.…”

Section: Introductionmentioning

confidence: 99%

LoC-SERS Platform Integrated with the Signal Amplification Strategy toward Parkinson’s Disease Diagnosis

Cao

Chen

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Multiplexed detection of Parkinson's disease (PD) biomarkers is of great significance for early diagnosis and personalized treatment. In this study, we fabricated a robust surface-enhanced Raman scattering-enabled lab-on-a-chip (LoC-SERS) platform for simultaneous quantification of α-synuclein, phosphorylated tau protein 181, osteopontin, and osteocalcin. Herein, the antibody−DNA conjugate was designed to introduce the catalytic hairpin self-assembly (CHA) amplification into the protein detection. Au nano-stars (AuNSs) modified with Raman reporter molecules and hairpin-structure DNA 1 were applied as the SERS nanotags. Au-coated silicon nanocone array (Au/ SiNCA) fabricated based on the maskless plasma etching-prepared high-density Si nanocone array (SiNCA) and surface ion sputtering was used as the capture substrate after the modification of hairpin-structure DNA 2. Benefitting from the antibody−DNA conjugateinduced CHA amplification, numerous AuNSs can be connected to the Au/SiNCA surface, which significantly amplify the plasmonic coupling effect for ultrasensitive SERS detection, and the limit of detection was less than the pg/mL level. The application of highly uniform Au/SiNCA and antibody−DNA conjugate endows the LoC-SERS platform excellent analytical performance, including superior reproducibility, satisfactory universality, and high sensitivity. In addition, a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model was established, and satisfactory results were obtained in real sample analysis with the LoC-SERS platform, which may be enlightening for exploiting protein biomarkers in PD monitoring.

show abstract

Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization

Cited by 12 publications

References 148 publications

Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat

Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat

Drug repurposing for Parkinson’s disease by biological pathway based edge-weighted network proximity analysis

LoC-SERS Platform Integrated with the Signal Amplification Strategy toward Parkinson’s Disease Diagnosis

Contact Info

Product

Resources

About